| Bioactivity | Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2]. |
| Invitro | Cantuzumab mertansine (SB-408075; huC242-DM1; 0-100 μM; 24 小时) 对抗原阳性 COLO 205 细胞系具有选择性细胞毒活性[1]。 Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | Cantuzumab mertansine (SB-408075; huC242-DM1; 300 μg/kg/天; 持续 5 天) 使携带 COLO 205 结肠癌人异种移植物的小鼠完全消退和治愈[1]。 Animal Model: |
| Name | Cantuzumab mertansine |
| CAS | 400010-39-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Paul R Helft, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 1;10(13):4363-8. [2]. Anthony W. Tolcher, et al. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol. 2003 Jan 15;21(2):211-22. |